Literature DB >> 16174287

Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases.

Byung Ha Chung1, Sun Woo Lim, Kyung Ohk Ahn, Akira Sugawara, Sadayoshi Ito, Bum Soon Choi, Yong Soo Kim, Byung Kee Bang, Chul Woo Yang.   

Abstract

Peroxisome proliferator activated receptor gamma (PPARgamma) agonist has not only antidiabetic effect but also a protective effect against various types of injury of the kidney. The protective effects of PPARgamma agonists are observed in diabetic nephropathy and non-diabetic renal diseases such as 5/6 ablation model of renal failure, experimental glomerulonephritis, ischemia-reperfusion injury, hypertensive nephropathy and cyclosporin-induced renal injury. The mechanism of renoprotection by PPARgamma agonist is multifactorial. Anti-fibrotic and anti-inflammatory effects, suppression of renin-angiotensin system, vascular protective effect and antiapoptotic effect were proposed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16174287     DOI： 10.1111/j.1440-1797.2005.00456.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN： 1320-5358            Impact factor:   2.506


  18 in total

Review 1.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 2.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

Review 3.  Mitochondrial energetics in the kidney.

Authors:  Pallavi Bhargava; Rick G Schnellmann
Journal:  Nat Rev Nephrol       Date:  2017-08-14       Impact factor: 28.314

4.  Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention.

Authors:  Kosmas I Paraskevas; Ioannis Kotsikoris; Sotirios A Koupidis; Alexandros A Tzovaras; Dimitri P Mikhailidis
Journal:  Int Urol Nephrol       Date:  2010-06-24       Impact factor: 2.370

5.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

6.  Role of PPARα and Its Agonist in Renal Diseases.

Authors:  Ching-Feng Cheng; Hsi-Hsien Chen; Heng Lin
Journal:  PPAR Res       Date:  2010-11-08       Impact factor: 4.964

7.  Pioglitazone ameliorates renal ischemia reperfusion injury through NMDA receptor antagonism in rats.

Authors:  Amrit Pal Singh; Nirmal Singh; Preet Mohinder Singh Bedi
Journal:  Mol Cell Biochem       Date:  2016-05-20       Impact factor: 3.396

8.  PPAR-gamma agonists inhibit TGF-beta1-induced chemokine expression in human tubular epithelial cells.

Authors:  Wei-ming Wang; Hui-di Zhang; Yuan-meng Jin; Bing-bing Zhu; Nan Chen
Journal:  Acta Pharmacol Sin       Date:  2008-12-22       Impact factor: 6.150

Review 9.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

10.  Effects of Glycyrrhizic Acid on Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma), Lipoprotein Lipase (LPL), Serum Lipid and HOMA-IR in Rats.

Authors:  Chia Yoke Yin; Ton So Ha; Khalid Abdul Kadir
Journal:  PPAR Res       Date:  2010       Impact factor: 4.964
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.